"Treatment-free Remission is a new treatment goal in CML," said François- Xavier Mahon, Cancer Center of Bordeaux, Institut Bergonié and lead investigator of
More From BioPortfolio on "New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® ..."